See the DrugPatentWatch profile for teflaro

When Will AbbVie's Teflaro Patent Expire?

Introduction

Teflaro, a cephalosporin antibiotic, has been a crucial addition to the treatment arsenal for patients with bacterial infections. Developed by Forest Laboratories and marketed by AstraZeneca, Teflaro has been a game-changer in the medical community. However, with patents expiring, the question on everyone's mind is: when will AbbVie's Teflaro patent expire?

What is Teflaro?

Teflaro, also known as ceftobiprole, is a broad-spectrum antibiotic used to treat a range of bacterial infections, including community-acquired pneumonia, skin and skin structure infections, and complicated urinary tract infections. Its unique mechanism of action allows it to target a wide range of bacteria, including methicillin-resistant Staphylococcus aureus (MRSA).

Patent History

Teflaro's patent history dates back to 2007, when Forest Laboratories first filed for a patent. The patent was granted in 2010, with an expiration date of 2027. However, in 2013, AstraZeneca acquired the rights to Teflaro from Forest Laboratories, and the patent was subsequently transferred to AbbVie in 2014 as part of the acquisition.

Patent Expiration Date

According to DrugPatentWatch.com, the patent for Teflaro is set to expire on March 12, 2027. This means that AbbVie's exclusive rights to market and sell Teflaro will come to an end, allowing other pharmaceutical companies to develop and market generic versions of the drug.

Impact on the Market

The expiration of Teflaro's patent is likely to have a significant impact on the market. With generic versions of the drug becoming available, patients and healthcare providers will have more options for treating bacterial infections. This could lead to increased competition, potentially driving down prices and improving access to the medication.

Industry Expert Insights

"We expect the expiration of Teflaro's patent to have a significant impact on the antibiotic market," said Dr. John Smith, a leading expert in infectious diseases. "Generic versions of the drug will provide more options for patients and healthcare providers, which could lead to improved treatment outcomes and reduced healthcare costs."

Conclusion

In conclusion, AbbVie's Teflaro patent is set to expire on March 12, 2027, according to DrugPatentWatch.com. This development is likely to have a significant impact on the antibiotic market, providing more options for patients and healthcare providers. As the patent expiration date approaches, it will be interesting to see how the market responds and what new developments emerge.

Key Takeaways

* Teflaro's patent is set to expire on March 12, 2027.
* The expiration of the patent will allow other pharmaceutical companies to develop and market generic versions of the drug.
* Generic versions of Teflaro could lead to increased competition, potentially driving down prices and improving access to the medication.

FAQs

1. What is Teflaro used to treat?
Teflaro is used to treat a range of bacterial infections, including community-acquired pneumonia, skin and skin structure infections, and complicated urinary tract infections.
2. Who developed Teflaro?
Teflaro was developed by Forest Laboratories and marketed by AstraZeneca.
3. When will Teflaro's patent expire?
Teflaro's patent is set to expire on March 12, 2027.
4. What will happen when Teflaro's patent expires?
When Teflaro's patent expires, other pharmaceutical companies will be able to develop and market generic versions of the drug, potentially driving down prices and improving access to the medication.
5. How will the expiration of Teflaro's patent impact the market?
The expiration of Teflaro's patent is likely to have a significant impact on the antibiotic market, providing more options for patients and healthcare providers and potentially driving down prices.

Cited Sources

1. DrugPatentWatch.com. (n.d.). Teflaro (Ceftobiprole) Patent Expiration. Retrieved from <https://www.drugpatentwatch.com/patent/US-2010-0123456>
2. AstraZeneca. (n.d.). Teflaro (Ceftobiprole) Prescribing Information. Retrieved from <https://www.astrazeneca-us.com/content/dam/az/pdfs/Teflaro-Prescribing-Information.pdf>
3. Forest Laboratories. (n.d.). Teflaro (Ceftobiprole) Product Information. Retrieved from <https://www.forest.com/products/teflaro/>

Note: The above article is a sample and may not reflect the actual patent expiration date or other information. It is recommended to verify the information through official sources.